

Chr. Hansen gets patent for its probiotic strain in S Korea

01 March 2018 | News

This strain is known worldwide for its gastrointestinal health benefits and has now also been shown to hold immunity support benefits.



Denmark based bioscience company, Chr. Hansen has received an important patent in South Korea on one of its most clinically documented probiotic strains named BB-12 (Bifidobacterium animalis ssp. lactis).

This strain is known worldwide for its gastrointestinal health benefits and has now also been shown to hold immunity support benefits. The patent covers the BB-12 probiotic strain for use in a method of boosting the immune response in conjunction with an influenza vaccine. However, the health benefit of this probiotic strain should be seen in a much broader perspective as several clinical studies have demonstrated the immune modulating effect of BB-12.

Apart from South Korea, Chr. Hansen holds similar patents, on the BB-12 probiotic strain for use in a method of boosting the immune response in conjunction with an influenza vaccine, in Europe and China.